Despite this, to broaden the clinical utility of CTCs in guiding therapy decisions is relevant to explore the molecular features of CTCs, such as the HER2 expression - a well-established biomarker of prognosis and treatment response in BC (Table 2). This evidence concerns the gene ERBB2 and breast cancer.